VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
MCRBSeres Therapeutics, Inc.
$6.61$64M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMCRBEarnings History

MCRB logoSeres Therapeutics, Inc. (MCRB) Earnings History

Net Loss

14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$47M
● Net Loss
TTM EPS (Diluted)
$-4.89
Per share, diluted
YoY EPS Growth
+103.4%
Excellent
Net Margin
721.9%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-11910.1%
Gross Margin-423.8%
Return on Equity19.6%
Return on Assets4.1%
Record Annual Net Income$6MFY2025
Record Quarterly EPS$14.37Q3 2021
Consecutive Profitable Years2years
Q1 2026
Net Income-$20M
EPS (Diluted)$-2.08
YoY Growth+103.4%Excellent
QoQ Growth-29.9%Declining

Loading earnings history...

Seres Therapeutics, Inc. (MCRB) Earnings Overview

As of June 22, 2026, Seres Therapeutics, Inc. (MCRB) reported trailing twelve-month net income of -$47M, reflecting +103.4% year-over-year growth. The company earned $-4.89 per diluted share over the past four quarters, with a net profit margin of 721.9%.

Looking at the long-term picture, MCRB's historical earnings data spans multiple years. The company achieved its highest annual net income of $6M in fiscal 2025, representing a new all-time high.

Seres Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including NKTR (-$158M net income, -297.1% margin), MIRM (-$799M net income, -4.5% margin), ARWR (-$301M net income, -0.2% margin), MCRB has outperformed on profitability metrics. Compare MCRB vs NKTR →

MCRB Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
MCRB logoMCRBCurrent
-$47M$-4.89721.9%19.6%+103.4%—
NKTR logoNKTR
-$158M$-6.39-297.1%-217.9%-12.1%
MIRM logoMIRM
-$799M$-13.57-4.5%-8.6%+74.6%
ARWR logoARWR
-$301M$-2.11-0.2%-0.5%+99.8%
RCKT logoRCKT
-$209M$-1.87--60.3%+26.4%
EVGN logoEVGN
-$14M$-1.41-220.2%-63.3%+62.6%
Best in group
Lowest in group

MCRB Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$6M+4088.2%-$94M$0.64721.9%-11910.1%
2024$136,000+100.1%-$121M$-18.86--
2023-$114M+54.5%-$195M$-17.77--
2022-$250M-281.5%-$180M$-46.29--
2021-$66M+26.4%-$64M$-14.30-45.2%-44.5%
2020-$89M-26.8%-$88M$-22.34-268.3%-265.3%
2019-$70M+29.0%-$72M$-24.81-203.7%-208.3%
2018-$99M-10.7%-$100M$-48.57-350.0%-354.8%
2017-$89M+2.4%-$91M$-44.19-278.4%-284.7%
2016-$92M-67.2%-$93M$-46.00-420.7%-426.5%
2015-$55M-227.8%-$55M$-46.60--
2014-$17M-173.8%-$15M$-9.24--
2013-$6M-95.2%-$6M$-3.58--
2012-$3M--$3M$-1.75--

Download Data

Export MCRB earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MCRB — Frequently Asked Questions

Quick answers to the most common questions about buying MCRB stock.

What is MCRB earnings per share (EPS)?

MCRB trailing twelve-month (TTM) diluted EPS is $-4.89, reflecting +103.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Seres Therapeutics, Inc.'s net income?

Seres Therapeutics, Inc. (MCRB) trailing twelve-month net income is $-47M as of 2025. Earnings grew +103.4% year-over-year. Seres Therapeutics, Inc. has been profitable for 2 consecutive years.

Is MCRB profitable?

MCRB is not currently profitable on a TTM basis, reporting a net loss of $-47M. Net margin is +721.9%. Investors should monitor for a return to profitability.

What is MCRB's earnings growth rate?

MCRB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are MCRB's profit margins?

Seres Therapeutics, Inc. net profit margin is +721.9%, operating margin is -11910.1%, and gross margin is -423.8%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +19.6%.

Is MCRB growing earnings?

Yes, MCRB earnings are accelerating — EPS growth of +103.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-47M. Earnings momentum is strengthening.

What was MCRB's best earnings year?

Seres Therapeutics, Inc.'s highest annual net income on record is $6M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were MCRB's earnings last quarter?

MCRB's most recent reported quarter was Q1 2026. Net income was $-20M with diluted EPS of $-2.08. For a full breakdown of all quarters, see the quarterly earnings table on this page.

MCRB Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view